Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.10 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)878.94K
Market Cap
$3.01B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.35B
Total Debt (Recent Filing)$51.72M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 08, 2025EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding93,680,130
10 Day Avg. Volume819,090
30 Day Avg. Volume878,944
Financial Highlights & Ratios
PEG Ratio-19.86
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$74.00Price Target Upside128.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Crinetics Pharmaceuticals News
PremiumCompany Announcements
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
PremiumCompany Announcements
Crinetics Pharmaceuticals Reports Q1 2025 Financial ResultsBulls Say, Bears Say
Bulls Say
Drug DevelopmentPaltusotine has a unique value proposition and no competition in surgically naïve patients with acromegaly.
Financial PositionThe company finished the quarter with $1.3B in cash, cash equivalents, and investments, which is expected to fund operations into 2029.
Regulatory ProgressRegulatory engagements have been proceeding 'on track' leading up to paltusotine PDUFA date, with management not anticipating an AdCom as part of NDA review.
Bears Say
Clinical TrialsThe additional cohort in the ongoing Phase 2 trial of atumelnant includes morning dosing, which may provide greater dosing flexibility and potentially better disease control.
Market CompetitionPaltusotone is expected to receive a broad label and uniform reimbursement for both the first-line 'treatment' setting and second-line 'maintenance' setting, enabling access without first attempting first-generation somatostatin analogs.
Pipeline DevelopmentCRNX plans to start Phase 3 trials in adults and pediatric CAH patients next year, indicating further progress and development.
Ownership Overview
2.08% Insiders
39.78% Mutual Funds
37.57% Other Institutional Investors
3.96% Public Companies and Individual Investors
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $3.01B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Aug 08, 2025 which is in 63 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on May 08, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.941 by -$0.099.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.1.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 93,680,130 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.941. Following the earnings report the stock price went down -6.177%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (128.96% Upside)
$74.00 (128.96% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 494.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.11%
12-Months-Change
Fundamentals
Return on Equity
-30.84%
Trailing 12-Months
Asset Growth
39.17%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals (CRNX) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting endocrine diseases and cancers. The company specializes in developing oral small-molecule drugs that address significant unmet needs in endocrinology, with a pipeline including treatments for conditions such as acromegaly, neuroendocrine tumors, and congenital adrenal hyperplasia.
CRNX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Crinetics Pharmaceuticals, Inc. with significant progress in regulatory approvals, strong financial positioning, and preparations for the commercial launch of paltusotine. However, the decrease in revenue and increase in operating expenses present challenges.Read More>CRNX Stock 12 Month Forecast
Average Price Target
$74.00
▲(128.96%Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―